Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) operates at the forefront of synthetic biology, combining cell programming expertise with biosecurity solutions for industries ranging from pharmaceuticals to agriculture. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and technological advancements.
Access real-time announcements including earnings reports, R&D breakthroughs, and strategic partnerships that demonstrate Ginkgo's leadership in biological engineering. The platform serves as a comprehensive resource for tracking developments in their core Cell Engineering services and Biosecurity programs.
Discover updates on Ginkgo's AI-driven innovations, government contracts, and cross-industry collaborations that shape the future of synthetic biology. Content is curated to help stakeholders understand how biological engineering advancements translate to commercial opportunities.
Bookmark this page for streamlined access to verified financial disclosures, operational milestones, and analysis of emerging trends in cell programming technology. Regular updates ensure you stay informed about developments impacting DNA's market position and sector leadership.
Light Bio has partnered with Ginkgo Bioworks (NYSE: DNA) to enhance the performance of bioluminescent plants. Ginkgo will apply its plant cell assays to improve the luminescent efficiency of Light Bio's glowing plants, which utilize enzymes derived from bioluminescent mushrooms. CEO Keith Wood of Light Bio expressed enthusiasm about the collaboration aiming for significant improvements in luminous output. The partnership leverages Ginkgo's advanced biotechnology capabilities to create innovative biodesigns, opening new market opportunities in ornamental plant applications.
FREDsense Technologies partners with Ginkgo Bioworks (NYSE: DNA) to develop biosensors for water quality monitoring. This collaboration aims to create four unique microbial strain biosensors compatible with FREDsense's portable hardware, allowing for real-time detection of harmful molecules in water sources. The partnership addresses the increasing demand for efficient water testing solutions and aims to enhance environmental and public health. CEOs from both companies express excitement about leveraging synthetic biology for critical water safety applications.
On April 12, 2022, Persephone Biosciences and Ginkgo Bioworks (NYSE: DNA) announced a collaboration aimed at developing novel therapeutics utilizing the Bacteroides bacterial genus. The partnership will focus on engineering Bacteroides species as a critical element in microbiome medicines, leveraging Ginkgo's synthetic biology platform. This collaboration is expected to enhance Persephone's capabilities in the microbiome space and could expedite the development of microbial therapies that improve patient outcomes.
Elanco Animal Health and Ginkgo Bioworks have launched BiomEdit, a new company focused on microbiome innovations for animal health. BiomEdit aims to develop probiotics and other solutions addressing urgent needs in livestock health, including antibiotic resistance. With an initial funding of $40 million, BiomEdit will operate independently, utilizing Elanco’s microbiome R&D expertise and intellectual property. This strategic separation allows Elanco to concentrate more effectively on its late-stage pet health pipeline while facilitating the growth of BiomEdit in the animal health sector.
Twist Bioscience Corporation (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) announced a new four-year supply agreement, enhancing their collaboration in synthetic biology. This agreement marks an increase in Ginkgo's commitments to purchase synthetic DNA from Twist to support its growth across various industries, including vaccine manufacturing and agriculture. The partnership builds on a previous agreement from 2017, highlighting a significant order of approximately one billion base pairs of synthetic DNA.
Microba Life Sciences Limited (ASX: MAP) has commenced trading on the Australian Securities Exchange after raising
Microba Life Sciences (ASX: MAP) and Ginkgo Bioworks (NYSE: DNA) have formed a partnership to identify live bacteria product candidates for autoimmune diseases. Leveraging Ginkgo's high-throughput screening, the collaboration aims to enhance Microba's strain evaluation capabilities. As part of this initiative, Ginkgo is investing $3.5 million in Microba, which is set to launch its Initial Public Offering on April 5, 2022. This partnership highlights the growing interest in microbiome-based therapeutics for chronic diseases.
Ginkgo Bioworks reported strong financial results for 2021, with total revenue reaching $314 million, a remarkable 309% increase from 2020. The company added 31 new Cell Programs, representing a 72% growth year-over-year. Despite a $1.8 billion loss from operations, largely due to stock-based compensation adjustments, Ginkgo maintains a strong cash position with over $1.5 billion. For 2022, Ginkgo anticipates total revenue between $325 million and $340 million and expects to add 60 new Cell Programs.
The joint COVID-19 testing program by Concentric by Ginkgo, the CDC, and XpresCheck identified Omicron sublineages BA.2 and BA.3 ahead of other U.S. reports. This traveler-based genomic surveillance program, conducted at major U.S. airports, enrolled international travelers voluntarily from September 2021 to January 2022. The findings suggest that the program effectively monitors variants and can enhance public health responses. Leaders from the CDC and XpresCheck emphasized its importance in detecting variants and supporting a robust biosecurity infrastructure.
Ginkgo Bioworks (NYSE: DNA) announced a presentation and Q&A session on March 28, 2022, to review business performance for the fourth quarter and full year ended December 31, 2021. The session will begin at 4:30 p.m. ET, with details available on their investor relations site. Additionally, the company will hold its annual shareholder meeting on June 10, 2022, allowing participation through a virtual platform for shareholders of record as of April 14, 2022.
